Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus

OBJECTIVES: To identify predictors of low disease activity and clinical remission following belimumab treatment in SLE. METHODS: SLE patients who received belimumab 10 mg/kg (N = 563) in the BLISS-52 and BLISS-76 clinical trials were surveyed. The performance of baseline factors in predicting attain...

Descripción completa

Detalles Bibliográficos
Autores principales: Parodis, Ioannis, Johansson, Petter, Gomez, Alvaro, Soukka, Sofia, Emamikia, Sharzad, Chatzidionysiou, Katerina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880848/
https://www.ncbi.nlm.nih.gov/pubmed/31157891
http://dx.doi.org/10.1093/rheumatology/kez191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880848/
https://www.ncbi.nlm.nih.gov/pubmed/31157891
http://dx.doi.org/10.1093/rheumatology/kez191

Ejemplares similares